Pioglitazone and Losartan Provides Additional Renoprotection
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
Peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are
currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or
in combination with insulin.angiotensin II receptor antagonist losartan reduced the levels of
proteinuria.Whether Combination therapy with pioglitazone and losartan provides additional
renoprotection in subjects with type 2 diabetic nephropathy,it's worth researching.